GUTS 株価分析 — Fractyl Health, Inc. Common Stock (Healthcare >> Biotechnology)
GUTS に関するよくある質問
GUTSのPER(株価収益率)は?
Fractyl Health, Inc. Common Stock(GUTS)は現在PER 11.79倍で取引されています。
GUTSのROE(自己資本利益率)は?
Fractyl Health, Inc. Common StockのROEは-505.22%です。
GUTSの配当利回りは?
Fractyl Health, Inc. Common Stockの配当利回りは0.00%です。
GUTSの品質スコア(Quality Score)は?
当社のAIはGUTSの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
GUTSは今が買い時ですか?
当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
GUTSはどのセクターに属しますか?
Fractyl Health, Inc. Common StockはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
GUTS AI Analysis Summary
Our AI summary for GUTS: Fractyl Health, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 11.79, ROE of -505.22%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.69
Price
0.00
(0.00%)
Day Change
|
|
|---|
GUTS, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.69 |
| PBV / Sector |
5.08 / 44,105.10
|
| Earning Per Share | -0.68 |
| PE / Sector |
11.79 / 19.37
GOOD
|
| PEG or PE/Growth / Sector |
0.44 / 1.06
GOOD
|
| Average 1M Daily Value |
1.61 M
GREAT
|
| Average 1W Daily Value |
0.56 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
39% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-06 08:00:05 |
| Symbol | GUTS |
| Name | FRACTYL HEALTH, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 158.65 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 108.67 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3 Van de Graaff Drive, Burlington, MA, United States, 01803
Phone: 781 902 8800
Website: https://fractyl.com
Employees: 100
Sector: Healthcare >> Biotechnology
Description: Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google